Compare Cintas Corporation (CTAS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Cintas Corporation trades at $194.36 (market cap $73.76B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Cintas Corporation is far larger — about 769.5× Inovio Pharmaceuticals Inc's market cap, and Cintas Corporation pays a 0.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTAS | INO | |
|---|---|---|
Market Cap | $73.76B | $95.85M |
Sector | Industrials | Health |
52-Week High | $226.27 | $2.87 |
52-Week Low | $163.55 | $1.05 |
Enterprise Value | $76.49B | $66.86M |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $183.75, up 2.29% on the day, with a bullish technical outlook supported by moving averages and strong support at $182. The company shows robust fundamentals with revenue growing to $10.34B in 2025 and net income reaching $1.81B, though valuation ratios like P/E of 38.77 appear elevated. Recent news highlights upcoming Q4 earnings and continued recognition as a top employer.
The stock offers a compelling growth story with consistent earnings beats and a 43-year dividend growth track record, but faces risks from high valuation and economic sensitivity. Analyst consensus is mixed with a $212.50 price target, suggesting moderate upside potential if execution remains strong amid competitive pressures.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
